Insmed announces redemption of all $225 million of outstanding 1.75% convertible senior notes due 2025

Bridgewater, n.j. , june 27, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% convertible senior notes due 2025 (the "notes") (cusip no.
INSM Ratings Summary
INSM Quant Ranking